Kymera's lead pipeline candidate received some good news. Shares of Kymera Therapeutics (KYMR 23.66%) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi, plans to expand the ongoing phase 2 studies evaluating experimental drug KT-474 in treating two skin conditions: hidradenitis suppurativa and atopic dermatitis. Sanofi opted to expand the phase 2 studies of KT-474 to accelerate the advan ...